https://www.selleckchem.com/pr....oducts/Gefitinib.htm
18; 95% confidence interval (CI) 1.68-2.82, 0.001). After PSM, we extracted 5,652 patients treated within CTO and 5,652 patients with non-CTO PCI. CTO PCI was also related to a higher frequency of CAPs (OR = 1.89; 95% CI 1.11-3.31, = 0.01). The frequency of periprocedural complications and CAPs remained stable during the assessed period of time. CTO PCI was confirmed to be among the predictors of increased CAP rate in the overall group of patients treated within CTO. The frequency of periprocedural complications and CAPs remained